52-Week Performance Chart

Powered by FactSet Research Systems Inc

Recent Company News

More

Powered by FactSet Research Systems Inc.

Corporate Actions/Books Closed

Go to Archived DR Corporate Actions

No DR Events are available.

Data provided by Thomson Reuters

Recent Dividends & Distributions

More
US RECORD DATE US PAYABLE DATE NET DR AMOUNT
Mar 31, 2025 TBA TBA
Sep 30, 2024 Dec 17, 2024 0.1926
Mar 28, 2024 Jun 17, 2024 0.1750
Sep 29, 2023 Dec 18, 2023 0.1846

Institutional Ownership

More
TOP INSTITUTIONAL HOLDERS POSITION
Hantz Financial Services, Inc. 157,046
RhumbLine Advisers LP 33,873
Johnson Investment Counsel, Inc. 10,300
TOP MUTUAL FUND HOLDERS POSITION
Johnson International Fund 10,300
SP Funds S&P World (ex-US) ETF 6,373
Cambria Endowment Style ETF 53

Data provided by FactSet Research Systems Inc.

Important Notice to Investors of Unsponsored DRs and GDNs:

From time to time, BNY may pay a rebate to brokers that deposit shares with BNY for the issuance of unsponsored depositary receipts (DRs) or global depositary notes. BNY assumes no obligation or responsibility, and expressly disclaims any liability arising out of, or relating to, such rebates, including without limitation whether the rebate or any portion of it is passed on to the beneficial holders by the brokers.
Unsponsored DRs may be issued by multiple depositary banks servicing a particular DR program. Consequently, as a result of Depository Trust & Clearing Corporation (“DTCC”) practice, the actual cash distribution fees charged may differ from the BNY fees detailed in the fee schedule as fees will be charged in accordance with the fee schedule of the depositary bank that is considered to be the “First Filer”. The fees to be charged for any particular unsponsored cash distribution will be disclosed on the event announcement published by the “First Filer”. BNY takes no responsibility for the level of fees charged by any other depositary bank. The “First Filer” is the depositary bank that filed the first Form F-6 for a program with the U.S. Securities and Exchange Commission (“SEC”). In the event the actual “First Filer” does not have DRs outstanding for a program, the next depositary bank who filed a
Form F-6 with the SEC and has DRs outstanding will be deemed to be the First Filer for these purposes.

DR Details

DR Symbol ALPMY
CUSIP 04623U102
DR Venue OTC
DR ISIN US04623U1025
Ratio DR:ORD 1:1
First Filer DB
Underlying ISIN JP3942400007
Underlying SEDOL 6985383
Country Japan
Effective Date Oct 21, 2008
Depositary BK, CIT, DB, JPMC (Unsponsored)
Industry Pharma. & Biotech.
Astellas Pharma is mainly engaged in the research and development, manufacture, and sale of pharmaceuticals globally. The Company's main products include XTANDI, Prograf, Betanis/Myrbetriq/BETMIGA, XOSPATA, Evrenzo, PADCEV, and other. XTANDI is an androgen receptor signaling inhibitor indicated for the treatment of forms of advanced prostate cancer. Betanis/Myrbetriq/BETMIGA is for Overactive Bladder (OAB) treatment, a beta-3 adrenergic receptor agonist. XOSPATA is a FLT3 inhibitor for adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with a FLT3 mutation-positive. PADCEV (enfortumab vedotin) is a treatment for patients with locally advanced or metastatic urothelial cancer.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS Deposit Agreement
Annual Depositary Service up to $0.1000
Cancellation up to $0.1000
Cash Distribution up to $0.1000
Issuance up to $0.1000
Registrar Inspection up to $0.0000
Cash Distribution(Other) up to $0.1000
Rights - Issuance up to $0.1000
Stock Dividend up to $0.1000
Transfer up to $0.0000
Cable Fee per Cancellation $17.5000

Monthly Trading Summary

More
Month Month End DR Close Price DR Trading Volume Avg Day DR Trading Volume
Apr.25 9.91 6,523,403 310,638
Mar.25 9.66 1,929,400 91,876
Feb.25 9.71 4,187,977 220,420

Powered by FactSet Research Systems Inc.

This information and data is provided for general informational purposes only.  Certain displayed prices may not reflect direct quotes from any market or exchange, but may instead reflect an approximation of price based on a methodology that includes a calculation that includes the price of underlying securities and foreign exchange rate selected for such purpose. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to Terms of Use

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

Data provided by Thomson Reuters, Inc.

BNY.COM TERMS OF USE PRIVACY POLICY

© 2025 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes. Market data provided by ICE Data Services. ICE Limitations.
News provided by Comtex News Network and MarketWatch. Powered and implemented by FactSet. Legal Statement.

Certain information included in this website is proprietary to Mergent, Inc. (Mergent) Copyright © 2003-2025. Reproduction of such information in any form is prohibited. Because of the possibility of human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the use of such information. Mergent Terms of Use apply

Holdings information provided by FactSet Research Systems Inc. Copyright © 2003-2025 FactSet Research Systems Inc. All rights reserved.

Thomson Reuters Marks: The THOMSON REUTERS Kinesis Logo depicted below and THOMSON REUTERS

Redistributor shall display or print the Thomson Reuters Trademarks when Redistributor's Customers are given access to the Services.

Where Redistributor makes available on display any and all Thomson Reuters Marks attributable to the Services, Redistributor shall include the following language in the Help About section or in a general attribution page: "The THOMSON REUTERS Kinesis Logo and THOMSON REUTERS are trademarks of Thomson Reuters and its affiliated companies in the United States and other countries and used herein under license."

Additional Attribution Guidelines by Thomson Reuters: Redistributor shall display or print the following notice in the Help About section or in a general attribution page. "Copyright ©, Thomson Reuters, 1999-2025. All Rights Reserved. Use, duplication, or sale of this service, or data contained herein, except as described in the [Authorized Products name] Subscription Agreement, is strictly prohibited."

THOMSON REUTERS